HPV16 synthetic long peptide (HPV16-SLP) vaccination therapy of patients with advanced or recurrent HPV16-induced gynecological carcinoma, a phase II trial

Table 2 Patient vaccination and outcome

ID	Vaccination				Clinical outcome		Radiology results
	(n) injections	Additional treatment	Chemotherapeutic drug	Interval 1st Vac-Chemo (months)	Status	Survival (months)	Pre-post scans interval (months)	Baseline sum LD (mm)	Post vaccination sum LD (mm)	Target lesions	Non-target lesions (RECIST)
1	4				died	9	8.1	120	161	PD	PD
2	3	RT			died	21	6.4	52	70	PD	PD
3	3	CH + RT	Cisplatin/Topotecan	1.9	died	19	2.4	132	138	SD	PD
4	3				died	8	4.8	149	189	PD	PD
5	2				died	6	1.8	68	89	PD	PD
6	2				died	4
7	2	CH	Carboplatin/Gemcitabin	1.0	died	13	6.2	NE	NE	NE	NE
8	4	CHRT/SUR	Carboplatin/Taxol	4.2	died	26	5.5	31	61	PD	PD
9	4	CH	Cisplatin/Topotecan	4.0	died	26	3.9	67	67	SD	PD
10	4				died	25	4.7	68	88	PD	PD
11	4				died	7
12	3				died	15
13	4				died	5	3.6	87	80	SD	PD
14	4				died	7	1.3	112	151	PD	PD
15	3				died	8	3.5	0	0		PD
16	2				died	7
17	4	CH	Cisplatin/Topotecan	2.1	UK	20
18	0				died	4
19	4				died	15
20	4				died	37
21	4				died	12	4.7	63	79	PD	PD

CH, chemotherapy; CHRT, chemoradiation; LD, longest diameter; NE, not evaluable; PD, progressive disease; RT, radiotherapy; SD, stable disease, SUR, surgery. The interval between the 1^st vaccination and the chemotherapy after the vaccinations (1st Vac-Chemo) was calculated by using the date of first vaccination and the starting date of the given chemotherapy during/after the vaccinations as reference points.

ISSN: 1479-5876